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Despite the potential seriousness of reactions, awareness of
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Food protein–induced enterocolitis (FPIES) is a non-IgE cell-
mediated food allergy that can be severe and lead to shock.1
Despite the potential seriousness of reactions, awareness of
FPIES is low; high-quality studies providing insight into
pathophysiology, diagnosis, and management are lacking; and
clinical outcomes are poorly established. Unmet needs in the field
include identification of noninvasive biomarkers, understanding
of the pathophysiology and prevalence, and having uniform
approaches to diagnosis and management. This document
presents an executive summary of the first international consensus
based on available evidence and aims to assist practitioners in
their care of patients with FPIES. The full report is available
online as open access in this article’s Online Repository at
www.jacionline.org.
An international workgroupwas convened through theAdverse
Reactions to Foods Committee of the American Academy of
Allergy, Asthma & Immunology and the International FPIES
Association advocacy group.
A comprehensive literature review was performed with the
assistance of a research librarian, with searches run in PubMed/
Medline, Web of Science, and Embase. Excluding abstracts, a
total of 879 citations were identified through February 2014; of
these, 110 were included. Individual sections were written by
using subgroup teams, critiqued, and revised based on feedback
from all authors until consensus was achieved. Evidence was
graded according to the previously established grading system for
clinical practice guidelines used by the Joint Task Force on
Allergy Practice Parameters.2SECTION I: DEFINITION AND CLINICAL
MANIFESTATIONS
Summary Statement 1: Recognize FPIES as a potential
medical emergency, which presents as delayed onset of pro-
tracted emesis and/or watery/bloody diarrhea, culminatingin hemodynamic instability and hypotension in at least 15%
of reactions. [Strength of recommendation: Strong; Evidence
strength: IIa/IIb; Evidence grade: B]
FPIES is a non–IgE-mediated food allergy that typically
presents in infancy, with repetitive protracted vomiting that
begins approximately 1 to 4 hours after food ingestion. Vomiting
is often accompanied by lethargy and pallor and can be followed
by diarrhea. Delayed onset and absence of cutaneous and
respiratory symptoms suggest a systemic reaction different
from anaphylaxis.1,3 Severe cases can progress to hypothermia,
methemoglobinemia, acidemia, and hypotension, mimicking
sepsis.3-5 The FPIES clinical phenotype is influenced by the age
of onset, nationality, timing, and duration of symptoms and
associated IgE-mediated food allergy (Table I).
Summary Statement 2: Recognize that the symptompheno-
type in patients with FPIES is determined by the frequency of
food ingestion. [Strength of recommendation: Strong; Evi-
dence strength: IIa; Evidence grade: B]
The manifestations and severity of FPIES depend on the
frequency and dose of the trigger food, as well as the phenotype
and age of an individual patient.6-9 The distinct pattern of emesis
starting within 1 to 4 hours after food ingestion (acute FPIES) oc-
curs when the food is ingested intermittently or after a period of
avoidance (Tables I and II). Watery diarrhea (occasionally with
blood and mucous) develops in some cases within 5 to 10 hours
of ingestion and can be present for up to 24 hours.4,9-13 Symptoms
of acute FPIES usually resolve within 24 hours after food inges-
tion. In most children with acute FPIES, they arewell between ep-
isodes with normal growth.
Chronic FPIES is less well characterized compared with acute
FPIES and only reported in infants younger than 4 months of age
fed with cow’s milk (CM) or soy infant formula. Chronic FPIES
develops on regular/repeated ingestion of the triggering food,
presenting as chronic/intermittent emesis, watery diarrhea, and
failure to thrive (FTT; Table I) Severe chronic FPIES can lead to
dehydration and shock.6,14 Hypoalbuminemia and poor weight
gain can predict chronic CM-induced FPIES in young infants
with chronic gastrointestinal symptoms.10 With elimination of
the chronic FPIES food trigger or triggers, symptoms resolve,
but subsequent feeding (accidental exposure or oral food chal-
lenge [OFC]) induces an acute FPIES reaction within 1 to 4 hours
of food ingestion (Table I). The acute symptomatology after food
avoidance distinguishes chronic FPIES from food protein–
induced enteropathy, eosinophilic gastroenteritis, or celiac dis-
ease. Chronic FPIES is uncommon but appears to be diagnosed
more frequently in Japan and Korea.10,13,15SECTION II: EPIDEMIOLOGY
There is limited, wide-scale epidemiologic information
regarding FPIES.16 FPIES was recognized and formally defined
in the mid-1970s.6 A 10th revision of the International Statistical
Classification of Diseases and Related Health Problems code for
FPIES (K52.2) was implemented in October 2015. Before this, no
uniform International Classification of Diseases code existed.
FPIES prevalence estimates vary greatly. Katz et al12 presented
the only published prospective birth cohort noting a cumulative
incidence of infants with CM-induced FPIES of 3 per 1000 new-
borns born at a single hospital over 2 years (0.34%).
Summary Statement 3: Recognize that onset of FPIES to
CM and soy can occur at younger ages compared with FPIES
TABLE I. Proposed defining features for clinical phenotyping of FPIES
FPIES subtypes Defining features
Age of onset
Early Younger than age 9 mo
Late Older than age 9 mo
Severity
Mild-to-moderate Repetitive emesis with or without diarrhea, pallor, mild lethargy
Severe Repetitive projectile emesis with or without diarrhea, pallor, lethargy, dehydration, hypotension, shock,
methemoglobinemia, metabolic acidosis
Timing and duration of symptoms
Acute Occurs with intermittent food exposures, emesis starts usually within 1-4 h, accompanied by lethargy and pallor;
diarrhea can follow within 24 hours, with usual onset of 5-10 h. Usual resolution of symptoms within 24 h after
elimination of the food from the diet. Growth is normal, and child is asymptomatic during food trigger elimination.
Chronic Occurs with daily ingestion of the food (eg, feeding with CM- or soy-based formula in an infant); symptoms include
intermittent emesis, chronic diarrhea, poor weight gain, or FTT. Infants with chronic FPIES usually return to their
usual state of health within 3-10 d of switching to a hypoallergenic formula, although in severe cases temporary
bowel rest and intravenous fluids might be necessary. Subsequent feeding of the offending food after a period of
avoidance results in acute symptoms.
IgE positivity
Classic Food specific, IgE negative
Atypical Food specific, IgE positive
TABLE II. Proposed defining features of mild and severe acute FPIES
Mild-to-moderate acute FPIES Severe acute FPIES
Clinical features Required
d Vomiting (onset usually 1-4 h, can range from 30 min
to 6 h): few episodes of intermittent vomiting (1-3),
can be bilious
d Decreased activity level
d Pallor
d Self-resolving; the child is able to tolerate oral rehy-
dration at home
Optional
d Mild watery diarrhea, onset usually within 24 hours,
can be bloody (occasionally)
Required
d Vomiting (onset usually at 1-4 h, can range from
30 min to 6 h): projectile (forceful), repetitive (>_4),
bilious and dry heaving
d Altered behavior ranging from decreased activity to
lethargy
d Pallor
d Dehydration
d Requires intravenous hydration
Optional
d Hypotension
d Abdominal distention
d Hypothermia
d Diarrhea, onset usually within 24 hours, can be bloody
d Hospitalization
Laboratory features (optional,
when available)
d Increased white blood cell count with neutrophilia
d Thrombocytosis
d Stool might be positive for leukocytes, eosinophils, or
increased carbohydrate content
d Increased white blood cell count with neutrophilia
d Thrombocytosis
d Metabolic acidosis
d Methemoglobinemia
d Stool might be positive for leukocytes, eosinophils, or
increased carbohydrate content
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triggers. [Strength of recommendation: Strong; Evidence
strength: IIb-III; Evidence grade: C]
The most commonly reported FPIES triggers are CM, soy, and
grains.11,12,17 Soy-induced FPIES and combined soy/CM-
induced FPIES are common in the United States (approximately
25% to 50% in reported case series) but uncommon in Australia,
Italy, and Israel. Most reported solid food–induced FPIES is
attributable to rice and oat. Rice is the most commonly reported
grain trigger, except in Italy.18 Combined rice/oat-induced FPIES
has been reported in almost a third of cases of rice-induced FPIES
in both the United States and Australia.4,5,9 In contrast, fish-
induced FPIES is common in Italy and Spain but less commonelsewhere.18,19 Multiple factors can be involved to explain this
geographic variation, including differences in the populations
studied in the case series, presence of atopic disease, breast-
feeding and dietary practices, and yet-to-be-discovered genetic
factors.11,12,17,20
FPIES occurs once CM or soy-based formulas, solid foods,
or both are introduced into the infant’s diet, usually between 2
and 7 months of age.4,8,9,12,16,18,21 Infants with CM- and soy-
induced FPIES typically present at a younger age
(<6 months) compared with those with solid food–induced
FPIES (6-12 months) reflecting earlier introduction of CM
and soy. The median age of solid food–induced FPIES onset
is similar between most series (5-7 months), with grain-
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poultry (see Table E1 in this article’s Online Repository at
www.jacionline.org).4,5,8,9,16,22
Infants with CM/soy-induced FPIES at less than 2 months of
age were significantly more likely to manifest diarrhea, blood in
stool, and FTT compared with those presenting at more than
2 months of age (P < .05 for all comparisons).7,11,13,18,23-26 Older
infants were more likely to present with vomiting alone
(P < .05).27 An acute-on-chronic phenotype also exists, in which
neonates initially present with the chronic FPIES but, on acci-
dental ‘‘on-off’’ exposure, present with acute FPIES.6,14
FPIES to fish/shellfish and egg in adults, as described in a small
case series, is characterized by delayed-onset vomiting, persis-
tence of the diagnosis, and a history of previous food
tolerance.28,29
Summary Statement 4: Consider specific IgE testing of chil-
dren with FPIES to their trigger food because comorbid IgE-
mediated sensitization to triggers, such as CM, can infer a
greater chance of persistent disease. [Strength of recommen-
dation: Moderate; Evidence strength: IIb-III; Evidence
grade: C]
FPIES is immunologically distinct from IgE-mediated disease,
but many children with FPIES have comorbid atopy, including
eczema and food IgE sensitization. Studies from the United States
and Australia report frequent atopic coassociation, especially
eczema (31% to 57% of cases, see Table E2 in this article’s Online
Repository at www.jacionline.org), although this association is
rare in Korea, Israel, and Italy (0% to 9%).18
Children with FPIES can also have coexisting IgE-mediated
food allergy at presentation or on follow-up assessment, as
reported in 2% to 12% of patients.4,9,18 Caubet et al4 reported
that children with CM-induced FPIES and IgE sensitization to
CM (ie, atypical FPIES)8 were more likely to have persistence
of CM-induced FPIES after 3 years of age compared with those
without sensitization. Sensitization to other food proteins did
not appear to delay tolerance acquisition.
Summary Statement 5: Do not recommend any specific pre-
natal or postnatal food introduction/avoidance or health be-
haviors or advise patients regarding any specific genetic
factors known to moderate the risk of a patient with FPIES.
[Strength of recommendation: Weak; Evidence strength:
IIb-III; Evidence grade: C]
In the Israeli birth cohort no association was noted between the
development of FPIES and gestational age, maternal age, number
of siblings, maternal dairy consumption, or age of introduction of
CM, although an association was notedwith caesarian section and
Jewish religion (ie, a greater proportion had FPIES).12 US, Italian,
and Australian case series have not assessed prenatal or postnatal
risk factors.5,8,9,16-18,22,30,31
Summary Statement 6: Consider FPIES a heterogeneous
disorder associated with a number of geographic variations
in the features of disease, representing a spectrum of ‘‘syn-
dromes’’ as opposed to a uniform ‘‘syndrome.’’ [Strength of
recommendation: Strong; Evidence strength: IIb-III; Evi-
dence grade: B]
The majority of reports in the literature are from Western
countries and predominantly include subjects of white race.16
Japanese data suggest that different FPIES phenotypes might
exist based on dietary habits, race, or ethnicity.15 In Japanese in-
fants with FPIES, vomiting was observed in 100%, bloody stools
in 47%, and fever in 13% at the initial presentation. Forty-sevenpercent had detectable serum CM-specific IgE (sIgE), and 10%
reported symptoms during breast-feeding.13,19 This phenotype
appears distinct to Japan, which is in contrast to the vomiting-
predominant presentation without bloody stools in slightly older
infants more commonly reported in most other countries.16SECTION III: DIAGNOSIS OF FPIES
Summary Statement 7: Diagnose FPIES primarily based
on a clinical history of typical characteristic signs and symp-
toms with improvement after withdrawal of the suspected
trigger food. Exclude other potential causes and use OFCs
to help confirm the diagnosis if the history is unclear and there
is a favorable risk/benefit ratio. [Strength of recommenda-
tion: Strong; Evidence strength: IIb-III; Evidence grade: B]
A careful history is the most important diagnostic tool in the
evaluation of FPIES.3,32 Acute FPIES presents with a constella-
tion of unique and sometimes dramatic signs and symptoms.
The clinician must obtain details of all possible reactions, specific
symptoms, timing of symptoms in relation to food intake, all sus-
pected food triggers, and reproducibility of reactions with
repeated exposures to the suspect food or foods. In the vast major-
ity of patients with acute FPIES, history alone is sufficient to
make a diagnosis and identify trigger foods.
If the diagnosis is unclear after taking a careful history, OFCs
should be used as the gold standard to confirm the diagnosis.
There is no laboratory or other diagnostic procedure specific for
FPIES, although there are a variety of other laboratory tests to
help support the diagnosis and, more importantly, to rule out other
conditions, as discussed in Table III.
Infants presenting with a convincing history of FPIES likely do
not require challenges to confirm their initial diagnosis. The
revised diagnostic criteria for acute and chronic FPIES are
presented in Table IV. In fact, in the face of a clear history with
repeated reactions to the same food or foods, the risk of an
OFC might outweigh its benefits. OFCs are best reserved in the
initial diagnostic evaluation for cases in which the history is un-
clear, a food trigger is not identified, the time course of symptoms
is atypical, or symptoms persist despite removing the suspected
trigger food or foods from the diet. OFCs are highly useful to
determine whether FPIES has been outgrown (Table V).
In patients with chronic FPIES, the diagnosis can be unclear
based on the history alone. Given the less specific nature of
chronic FPIES symptoms, a trial of food elimination followed by
supervised OFCs to potential food triggers might be necessary for
a conclusive diagnosis. In select cases endoscopy and biopsy
might be warranted to exclude other causes.
Summary Statement 8: Conduct OFCs in patients with sus-
pected FPIES inmedically supervised settings in which access
to rapid fluid resuscitation is available and prolonged obser-
vation can be provided, if necessary. [Strength of recommen-
dation: Strong; Evidence strength: IIb; Evidence grade: B]
OFCs in patients with FPIES should be conducted with
caution; up to 50% of positive OFC results might require
treatment with intravenous fluids.32 Home OFCs to a food
suspected of triggering FPIES are not recommended given the
potential for severe reactions. Although one recent study reported
successful management of OFC reactions with oral rehydration
and anecdotally some reactions are managed with oral
rehydration,12 it is advisable to have intravenous hydration
readily available.
TABLE III. Differential diagnosis of FPIES
Condition Features that can distinguish from FPIES
Infectious gastroenteritis (eg, viral or bacterial) Single episode of illness, fever, sick contacts
Sepsis Fluid resuscitation alone not effective
Necrotizing enterocolitis Newborns and younger infants, rapid escalation of symptoms, bloody
stools, shock, intramural gas on abdominal radiographs
Anaphylaxis Symptoms begin within minutes to 2 hours of exposure, positive IgE test
results, usually other manifestations (eg, urticaria)
Food aversion Look at the familial context
Inborn errors of metabolism: urea cycle defects, hereditary fructose
intolerance, hyperammonemic syndromes, propionic/methylmalonic
acidemia, b-oxidation defects, hyperinsulinism-hyperammonemia
syndrome, pyruvate dehydrogenase deficiency, mitochondrial disorders,
maple syrup urine disease, ketothiolase deficiency
Developmental delay, neurologic manifestations, organomegaly, reaction
to fruits
Lactose intolerance In its severe form gas, bloating, cramps, diarrhea, borborygmi, and
vomiting after ingestion of liquid milk and large doses of dairy products
with lactose
Neurologic disorders (eg, cyclic vomiting) No relation to specific food intake
Gastrointestinal reflux disease Emesis more chronic and not usually severe (ie, does not lead to
dehydration), only upper gastrointestinal symptoms present
Hirschsprung disease Delay in passage of the first meconium, marked abdominal distention
FPIES Symptoms usually not temporarily associated with specific food intake;
symptoms more chronic than episodic; vomiting less severe; most
commonly implicated foods are CM, soy, wheat, and egg white
Eosinophilic gastroenteropathies (eg, eosinophilic esophagitis or
eosinophilic gastroenteritis)
Usually not associated with specific food intake, symptoms more chronic
than episodic, vomiting less severe, more likely to have positive IgE test
results
Celiac disease No temporal relationship between symptoms and specific food intake,
progressive malabsorption, results of celiac serology are positive
Immune enteropathies (eg, inflammatory bowel disease, autoimmune
enteropathy, or immunodeficiency)
Rare in infancy, not related to specific food intake
Obstructive problems (eg, malrotation, Ladd bands, or volvulus) Not related to specific food intake, evidence of obstruction on radiologic
studies
Coagulation defects No relation to specific food intake
a1-Antitrypsin deficiency No relation to specific food intake, hepatic involvement
Primary immunodeficiencies No relation to specific food intake, intestinal symptoms frequent infections
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published.3,6,32-34 All OFCs require close supervision with imme-
diate access to intravenous fluids. Some experts strongly recom-
mend that peripheral intravenous access be secured before the
OFC. A baseline complete blood cell count (CBC) with differen-
tial might be of value, especially in the research setting (as a
comparator with a postchallenge CBC) but is considered optional
in OFCs performed for clinical indications. Although some proto-
cols provide the entire dose in a single portion, the current
consensus is to administer the challenge food at a dose of 0.06
to 0.6 g, usually 0.3 g of the food protein per kilogram of body
weight, in 3 equal doses over 30 minutes. It is generally recom-
mended not to exceed a total of 3 g of protein or 10 g of total
food (100 mL of liquid) for an initial feeding (which aims to
approximate a serving size) and observe the patient for 4 to
6 hours.34 Lower starting doses, longer observation periods be-
tween doses, or both should be considered in patients with a his-
tory of severe reactions.32When a very low dose of food protein is
administered and there is no reaction after 2 to 3 hours of obser-
vation, some experts advocate that the patient ingest a full age-
appropriate serving of the food, followed by 4 hours of observa-
tion. However, in patients with detectable sIgE to the challenge
food, a more gradual administration of the challenge foodaccording to protocols for IgE-mediated food allergy is recom-
mended, with a longer postchallenge observation period to ac-
count for a possible FPIES reaction.34 The total dose and
dosing regimen for FPIES-related OFCs have not been systemat-
ically studied, and therefore practices can vary internationally; it
is ultimately at the physician’s discretion to modify the regimen
per the individual circumstances.
With a positive (eg, failed) OFC result, typical FPIES
symptoms, including emesis (usually protracted repetitive
emesis), pallor, and lethargy, begin within 1 to 4 hours after
ingestion. Diarrhea can occur in about 5 to 10 hours. If a CBC
with differential was obtained before and after challenge, there is
an increase in the neutrophil count (>1500 cells/mL), peaking
6 hours after food ingestion.4,6,14 In patients with diarrhea, a stool
sample can be assessed for the presence of occult blood, leuko-
cytes, or red blood cells. Revised criteria for interpretation of
OFC results are presented in Table V.
See Summary Statement 18 for treatment of acute reactions or
positive OFC results.
Summary Statement 9: Do not routinely perform testing for
food sIgE to identify food triggers of FPIES because FPIES is
not an IgE-mediated process. However, because some patients
with FPIES can exhibit coexisting IgE-mediated allergies,
TABLE IV. Diagnostic criteria for patients presenting with possible FPIES
Acute FPIES
Major criterion:
Vomiting in the 1- to 4-h period after ingestion of the suspect food and
absence of classic IgE-mediated allergic skin or respiratory symptoms
Minor criteria:
1. A second (or more) episode of repetitive vomiting after eating the
same suspect food
2. Repetitive vomiting episode 1-4 h after eating a different food
3. Extreme lethargy with any suspected reaction
4. Marked pallor with any suspected reaction
5. Need for emergency department visit with any suspected reaction
6. Need for intravenous fluid support with any suspected reaction
7. Diarrhea in 24 h (usually 5-10 h)
8. Hypotension
9. Hypothermia
The diagnosis of FPIES requires that a patient meets the major criterion and >_3 minor criteria. If only a single episode has occurred, a diagnostic OFC should
be strongly considered to confirm the diagnosis, especially because viral gastroenteritis is so common in this age group. Furthermore, although not a criteria
for diagnosis, it is important to recognize that acute FPIES reactions will typically completely resolve over a matter of hours compared with the usual
several-day time course of gastroenteritis. The patient should be asymptomatic and growing normally when the offending food is eliminated from the diet.
Chronic FPIES
Severe presentation: When the offending food is ingested on a regular
basis (eg, infant formula); intermittent but progressive vomiting and
diarrhea (occasionally with blood) develop, sometimes with dehydration
and metabolic acidosis.
Milder presentation: Lower doses of the problem food (eg, solid foods or
food allergens in breast milk) lead to intermittent vomiting and/or
diarrhea, usually with poor weight gain/FTT but without dehydration or
metabolic acidosis.
The most important criterion for chronic FPIES diagnosis is resolution of
the symptoms within days after elimination of the offending food(s) and
acute recurrence of symptoms when the food is reintroduced, onset of
vomiting in 1-4 h, diarrhea in 24 h (usually 5-10 h). Without
confirmatory challenge, the diagnosis of chronic FPIES remains
presumptive.
TABLE V. Diagnostic criteria for the interpretation of OFCs in
patients with a history of possible or confirmed FPIES
Major criterion Minor criteria
Vomiting in the 1- to 4-h period after
ingestion of the suspect food and
the absence of classic IgE-
mediated allergic skin or
respiratory symptoms
1. Lethargy
2. Pallor
3. Diarrhea 5-10 h after food
ingestion
4. Hypotension
5. Hypothermia
6. Increased neutrophil count of
>_1500 neutrophils above the
baseline count
The OFC will be considered diagnostic of FPIES (ie, positive) if the major
criterion is met with >_2 minor criteria. However, we would suggest 2
important caveats to these criteria: (1) with the rapid use of ondansetron,
many of the minor criteria, such as repetitive vomiting, pallor, and
lethargy can be averted, and (2) not all facilities performing challenges
have the ability to perform neutrophil counts in a timely manner.
Therefore the treating physician might decide that a challenge be
considered diagnostic in some instances, even if only the major criterion
was met. However, in challenges performed for research purposes,
providers should adhere to stringent criteria for challenge positivity.
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conditions. Assessment of chemistry or blood counts can
help rule out other causes of symptoms if obtained in the acute
setting. [Strength of recommendation: Moderate; Evidence
strength: III; Evidence grade: C]
The majority of patients with FPIES have negative skin prick
test (SPT) responses and undetectable serum food sIgE to the
suspect food at the time of their initial diagnosis.4,8,12,18,22However, IgE testing can be considered in patients with FPIES
at follow-up visits, as dictated by interval history, because 2%
to 20% might eventually have positive test responses to the sus-
pect FPIES-related food or foods and 20% to 40% will have pos-
itive test responses to other common food allergens.4,8,18 There
are some children who demonstrate sIgE to their trigger food
(so-called atypical FPIES) and have slower resolution of FPIES,
and these children are important to identify.8,35 Therefore peri-
odic testing (eg, before an OFC) for food sIgE can be considered
in patients with comorbid conditions, such as IgE-mediated food
allergy to other foods and atopic dermatitis believed to be influ-
enced by a food allergen, but this is not recommended at the initial
evaluation for an FPIES trigger. In patients with CM-induced
FPIES, CM sIgE levels should be measured before performing
a food challenge, given the risk of conversion to the IgE-
mediated CM allergy. Atopy patch tests have been evaluated in
2 small studies as a possible means of identifying specific food
sensitivities in patients with FPIES. Because of conflicting re-
sults, no recommendation regarding the utility of atopy patch tests
can be made.36,37
Patients with chronic FPIES demonstrate varying degrees of
anemia, hypoalbuminemia, and an increased white blood cell
count with a left shift and eosinophilia.10 This frequently leads to
sepsis evaluation in the emergency department.22 Thrombocyto-
sis was reported in 65% of patients in one acute FPIES series.9
Metabolic acidosis and methemoglobinemia were reported in pa-
tients with acute and chronic FPIES because of hemodynamic
shifts.38
In patients with acute FPIES with diarrhea, frank or occult
blood, mucus, leukocytes, and increased carbohydrate content
can all occur.6 In infants with chronic FPIES with diarrhea, stool
examination can reveal occult blood, neutrophils, eosinophils,
Charcot-Leyden crystals, and/or reducing substances.10 Gastric
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revealing more than 10 leukocytes/high-power field in 15 of 16
patients with positive OFC results and 0 of 8 patients with nega-
tive OFC results.39 These evaluations do not have clinical utility
for routine use, and even the acute leukocytosis seen in patients
with positive OFC results rarely adds to the overall interpretation
of the OFC outcome.
Summary Statement 10: Do not obtain radiographic testing
in the routine diagnostic work-up of suspected FPIES.
[Strength of recommendation: Strong; Evidence strength:
III; Evidence grade: C]
There is no radiographic finding specific to FPIES. Radiologic
studies performed in some older studies involving infants with
possible chronic FPIES symptoms showed air-fluid levels,
nonspecific narrowing and thumb printing of the rectum and
sigmoid, and thickening of the plicae circulares in the duodenum
and jejunum with excess luminal fluid.40 Intramural gas has been
documented, potentially leading to a misdiagnosis of necrotizing
enterocolitis.9
Summary Statement 11: Consider a broad differential for a
patient presenting with acute vomiting in making a diagnosis
of FPIES. [Strength of recommendation:Moderate; Evidence
strength: III/IV; Evidence grade: C]
An infant can present with multiple reactions before FPIES is
eventually considered, often leading to extensive diagnostic
evaluations, especially when FPIES is caused by solid foods.9,22
Delayed diagnosis is likely due to a combination of nonspecific
symptoms, the absence of definitive diagnostic tests, and an over-
all lack of familiarity with FPIES. Delayed diagnosis of solid
food–induced FPIES might also be due to the fact that rice, oat,
and vegetables uncommonly cause IgE-mediated food allergy.
The differential diagnosis of FPIES is extensive, as shown in
Table III. The initial episodes can be misdiagnosed as acute viral
gastroenteritis or be evaluated for sepsis, especially if they present
with profound lethargy, hypotension, and increased white blood
cell counts with a leftward shift.6,9
Summary Statement 12: Use distinct criteria to diagnose
FPIES in the outpatient/community setting compared with
the monitored setting in which OFCs are being used to rule
in the diagnosis. [Strength of recommendation: Weak; Evi-
dence strength: III/IV; Evidence grade: D]
Revised diagnostic criteria for patients presenting with
possible acute and chronic FPIES are presented in Table IV. These
criteria differ from Powell and Sicherer’s criteria in that they
eliminate an age limit for onset of FPIES and emphasize repetitive
vomiting as a cardinal feature of acute FPIES based on more
recent literature.5,6,8,9,11,12,18,28,41 Specific major and minor
criteria for acute FPIES are provided based on the collective pub-
lished evidence. The major criterion for acute FPIES is vomiting
in the 1- to 4-hour period after ingestion of the suspect food and
the absence of classic IgE-mediated allergic skin or respiratory
symptoms. Minor criteria include the following:
1. a second (or more) episode of repetitive vomiting after
eating the same suspect food;
2. a repetitive vomiting episode 1 to 4 hours after eating a
different food;
3. extreme lethargy with any suspected reaction;
4. marked pallor with any suspected reaction;
5. need for emergency department visit with any suspected
reaction;6. need for intravenous fluid support with any suspected
reaction;
7. diarrhea in 24 hours (usually 5–10 hours);
8. hypotension; and
9. hypothermia.
The diagnosis of FPIES requires that a patient meets the major
criterion and at least 3 minor criteria. If only a single episode has
occurred, a diagnostic OFC should be strongly considered to
confirm the diagnosis, especially because viral gastroenteritis is
so common in this age group.
General criteria are provided for patients with chronic FPIES,
but given the paucity of published reports of chronic FPIES,
specific major and minor criteria could not be established at this
time.
For severe chronic FPIES, when the offending food is ingested
on a regular basis (eg, infant formula), intermittent but progres-
sive vomiting and diarrhea (occasionally with blood) develop,
sometimes with dehydration and metabolic acidosis. For milder
chronic FPIES, lower doses of the problem food (eg, solid foods
or food allergens in breast milk) lead to intermittent vomiting,
diarrhea, or both, usually with poor weight gain/FTT but without
dehydration or metabolic acidosis.
It is important to recognize 2 distinct hallmarks of chronic
FPIES: patients are asymptomatic and maintain normal growth
when the trigger food is eliminated from the diet, and reintro-
duction of the trigger food induces acute FPIES symptoms. The
diagnostic criteria for the interpretation of OFC results in patients
with a history of possible or confirmed FPIES are presented in
Table V. These criteria also differ in the degree of neutrophilia and
remove the stool laboratory findings, reflecting a possible pheno-
typic shift represented by a lower frequency of diarrhea and
smaller magnitude of neutrophil count increase during OFCs, as
reported in the recent literature.4,11,12SECTION IV: PATHOPHYSIOLOGY OF FPIES
FPIES can involve antigen-specific T cells, antibodies, and
cytokines as a cause of the inflammation found in the colon and, to
variable degrees, the ileum by means of endoscopy, colonoscopy,
and biopsy.39,42-48 This inflammation is believed to cause an
increased intestinal permeability and fluid shift into the gastroin-
testinal lumen.49
Summary Statement 13: Classify FPIES as a non–IgE-
mediated food allergy but be aware that the postulated T
cell–mediated mechanism of FPIES requires further valida-
tion. [Strength of Recommendation: Strong; Evidence
strength: IIb/III; Evidence grade: C]
FPIES is classified as a non–IgE-mediated disorder.1,8,22,50
However, some patients with FPIES have IgE to the trigger
food, which might be associated with a more protracted course,
in particular casein in patients with CM-induced FPIES.4,22,32
Phenotypic shifting from IgE-mediated CM-induced allergy to
pure FPIES has been reported.51 Local intestinal mucosal IgE an-
tibodies could facilitate antigen uptake and lead to intestinal
inflammation. TH2 responses similar to those occurring in pa-
tients with IgE-mediated allergy have been found in patients
with FPIES.52,53 This corroborates the observation of high rates
of atopy in patients with FPIES.3,4 The relationship between
IgE and non-IgE mechanisms in patients with FPIES requires
further investigations. Reported successful use of ondansetron
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challenges implies neuroimmune mechanism involvement.54,55SECTION IV: GASTROINTESTINAL
MANIFESTATIONS OF FPIES
Summary Statement 14: Do not routinely obtain endo-
scopic evaluation as part of the evaluation of FPIES.
[Strength of recommendation: Weak; Evidence strength:
IV; Evidence grade: D]
In patients with chronic FPIES with emesis and FTT, upper
endoscopy can reveal gastric edema, erythema, and mucosal
friability, with gastric antral erosions.46 Colonoscopy results can
be normal in the absence of rectal bleeding or diarrhea.42,43,56,57
In patients with rectal bleeding, loss of vascular pattern,
spontaneous and induced friability, and variable degrees of
ulceration with spontaneous bleeding can occur. Rectal histology
ranges from slight infiltrate of lymphocytes and plasma cells in
the lamina propria to polymorphonuclear leukocytic infiltration
of the lamina propria or glands, with occasional crypt abscesses
and depletion of mucus from rectal glands. Destruction of the
surface epithelium can be seen. Colonic macroscopic appearance
is similar to that of the rectum, with red, fragile, hemorrhagic
mucosa seen within a few hours of ingesting the offending food.56
Colonic biopsy specimens show severe inflammation with
increased eosinophil numbers.56 In some infants with FPIES,
small intestinal damage with variable degrees of villous atrophy
has been described.24 Clinically, enteropathy can cause carbohy-
drate malabsorption and watery stools, which are positive for
reducing substances.6,57 Gross and histologic abnormalities can
revert to normal as soon as 2 days after removal of the trigger
food.42
Summary Statement 15: Do not use stool tests to make the
diagnosis of FPIES. [Strength of recommendation:Weak; Ev-
idence strength: III; Evidence grade: D]
Stool eosinophils, detected by using Hansel’s stain, along with
eosinophilic debris can be found in infants with FPIES.57 Results
of stool cultures and/or evaluation of stool for pathogenic organ-
isms, including parasites, should be negative. Stool leukocytes
noted on trigger food challenge were included among Powell’s
diagnostic criteria of FPIES, although this specific feature is
rarely considered essential in light of Sicherer’s modification to
the acute FPIES criteria.57 In addition, patients with chronic
FPIES can have occult fecal or frank blood after elimination
and then reintroduction of the trigger food to their diets.12,17,57
Summary Statement 16: Consider a work-up to rule out
other gastrointestinal diseases resulting in symptoms that
overlap with FPIES. [Strength of recommendation: Moder-
ate; Evidence strength: III; Evidence grade: D]
A broad differential must be considered given that many
infantile gastrointestinal disorders cause symptoms overlapping
with chronic FPIES (Table III).SECTION VI: MANAGEMENT OF ACUTE FPIES
Summary Statement 17: Treat acute FPIES as a medical
emergency and be prepared to provide aggressive fluid resus-
citation because approximately 15% of patients can have hy-
povolemic shock. [Strength of recommendation: Strong;
Evidence strength: IIa; Evidence grade: B]Summary Statement 18: Manage acute FPIES individually
according to severity and review treatment strategies with the
caregivers of each patient. [Strength of recommendation:
Moderate; Evidence strength: IIb/III; Evidence grade: C]
Acute FPIES can result readily in hypovolemic shock and
should be managed appropriately whether from a positive OFC
result or accidental exposure. The priority in management of
severe FPIES is restoration of stable hemodynamics through
aggressive isotonic fluid resuscitation (eg, 10-20 mL/kg boluses
of normal saline) repeated as needed and dextrose saline as a
continuous intravenous maintenance infusion (Table VI).
A single dose of intravenous methylprednisolone (1 mg/kg;
maximum, 60-80 mg), can decrease presumed cell-mediated
inflammation, although no studies support this recommenda-
tion.33 In severe reactions patients might require supplemental
oxygen, mechanical ventilation, or noninvasive positive pres-
sure ventilation for respiratory insufficiency or failure, vaso-
pressors for hypotension, bicarbonate for acidemia, and
methylene blue for methemoglobulinemia.3,28,32,38,58,59
Epinephrine autoinjectors are not routinely recommended/pre-
scribed for FPIES, although those with concomitant IgE-
mediated allergy should be prescribed epinephrine autoinjector
at the physician’s discretion if the patient is deemed at risk for
food-induced anaphylaxis.1 Mild-to-moderate acute FPIES can
resolve with oral rehydration, including breast-feeding, at home
(Table VII).
Summary Statement 19: Consider ondansetron as an
adjunctive management of emesis in patients with acute
FPIES. [Strength of recommendation: Weak; Evidence
strength: IV; Evidence grade: D]
Ondansetron is a serotonin 5-HT3 receptor antagonist used to
treat nausea and vomiting, often after chemotherapy, but is used
also in patients with viral gastroenteritis. Special caution might
be warranted in children with heart disease because of the poten-
tial to prolong the QT interval.60 Two small case series reported
that use of intravenous ondansetron was helpful in stopping
emesis during FPIES-related OFCs.54,55 This intervention is
promising, but its use is poorly studied at present. Rigorous trials
are needed to determine the role and efficacy of ondansetron in the
management of acute FPIES.
Summary Statement 20: Use dietary elimination of the
trigger food or foods for the primary management of FPIES
and educate caregivers and other care providers regarding
avoidance strategies. [Strength of recommendation: Strong;
Evidence strength: IIb/IIIIV; Evidence grade: C]
Long-term FPIES management involves elimination of the
trigger food or foods, plans for dietary advancement, treatment of
symptoms at presentation or on re-exposure (including emer-
gency treatment planning), and monitoring for FPIES resolution.
Nutritional consultation should be strongly considered for any
patient, irrespective of the number of food avoidances recom-
mended, to ensure adherence to dietary avoidance and adequate
nutrition.
Infants with suspected CM- or soy-induced FPIES are
generally advised to avoid all forms of these foods, including
baked and processed foods, unless they are already included in
the diet.1,3,61 There are no conclusive studies to date evaluating
tolerance to CM and egg proteins in baked products in children
with FPIES, although a small case series reported tolerance of
baked CM and egg in some children. Introduction of baked
CM and egg should be done under physician supervision
TABLE VI. Management of acute FPIES episode at the medical facility
Presenting symptoms
Mild Moderate Severe
Symptoms
1-2 Episodes of emesis
No lethargy
>3 Episodes of emesis and mild lethargy >3 Episodes of emesis, with severe lethargy,
hypotonia, ashen or cyanotic appearance
Management
1. Attempt oral rehydration (eg, breast-
feeding or clear fluids)
2. If age 6 mo and older: consider ondanse-
tron intramuscular, 0.15 mg/kg/dose;
maximum, 16 mg/dose
3. Monitor for resolution about 4-6 h from
the onset of a reaction
1. If age greater than 6 mo: administer on-
dansetron intramuscular 0.15 mg/kg/dose;
maximum, 16 mg/dose
2. Consider placing a peripheral intravenous
line for normal saline bolus 20 mL/kg,
repeat as needed
3. Transfer the patient to the emergency
department or intensive care unit in case
of persistent or severe hypotension, shock,
extreme lethargy, or respiratory distress
4. Monitor vital signs
5. Monitor for resolution at least 4-6 h from
the onset of a reaction
6. Discharge home if patient is able to
tolerate clear liquids
1. Place a peripheral intravenous line and
administer normal saline bolus, 20 mL/kg
rapidly; repeat as needed to correct
hypotension
2. If age 6 mo and older: administer intrave-
nous ondansetron, 0.15 mg/kg/dose;
maximum, 16 mg/dose
3. If placement of intravenous line is delayed
because of difficult access and age is 6 mo
or older, administer ondansetron intra-
muscular, 0.15 mg/kg/dose; maximum,
16 mg/dose
4. Consider administering intravenous meth-
ylprednisolone, 1 mg/kg; maximum,
60-80 mg/dose
5. Monitor and correct acid base and electro-
lyte abnormalities
6. Correct methemoglobinemia, if present
7. Monitor vital signs
8. Discharge after 4-6 h from the onset of a
reaction when the patient is back to base-
line and is tolerating oral fluids
9. Transfer the patient to the emergency
department or intensive care unit for
further management in case of persistent
or severe hypotension, shock, extreme
lethargy, respiratory distress
Strong consideration should be lent to performing food challenges in children with a history of severe FPIES in the hospital or other monitored setting with immediate availability
of intravenous resuscitation. Oral challenges in the physician’s office can be considered in patients with no history of a severe FPIES reaction, although caution should be urged
because there are no data that can predict the future severity of FPIES reactions.
TABLE VII. Management of acute FPIES episode at home
Current episode MildA,B Moderate-to-severe
Symptoms 1-2 Episodes of emesis
No or mild lethargy
>3 Episodes of emesis and moderate-to-severe lethargy
Management Attempt oral rehydration at home (eg, breast-feeding or clear fluids) Call 911 or go to the emergency department
A. Child with history of severe FPIES reaction: call 911 or go to the emergency department if the triggering food was definitely ingested, even in the absence of symptoms or with
any symptoms regardless of severity.
B. Child with no history of severe FPIES reaction.
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this practice.62-67
Infants with CM/soy-induced FPIES can be breast-fed or use a
hypoallergenic formula, such as casein-based extensively hydro-
lyzed formula. When possible, breast-feeding should be
continued, which is consistent with official recommendations
for infant feeding.68 Ten percent to 20% might require an amino
acid–based formula (AAF).4,22 In infants with CM-induced
FPIES, introduction of soy formula should be considered under
a physician’s supervision and vice versa.
The risk of coreactivity to CM and soy is reported in
approximately 20% to 40% of US patients but is noticeably
absent in similar reports from Australia, Israel, and Italy.9,12,18
Based on high homology of the protein sequences in these animal
milks, goat and sheep milk are not recommended in patients withCM-induced FPIES.61 It is possible that milks from donkeys,
camels, or both might be tolerated in patients with CM-induced
FPIES because they are usually well tolerated in those with
IgE-mediated CM allergy. Infants with chronic FPIES usually re-
turn to their usual state of health within 3 to 10 days of switching
to a hypoallergenic formula, although in severe cases temporary
bowel rest and intravenous fluids might be necessary.6,14
Summary Statement 21: Do not recommend routine
maternal dietary elimination of offending triggers while
breast-feeding if the infant is thriving and remains asymptom-
atic. [Strength of recommendation: Moderate; Evidence
strength: III-IV; Evidence grade: C]
The majority of infants do not react to food allergens present in
maternal breast milk. In the case of symptomatic FPIES occurring
in an exclusively breast-fed infant, the mother should eliminate
TABLE VIII. Common food coallergies in children with FPIES
FPIES to:
Clinical cross-reactivity/
coallergy
Observed
occurrence*
CM Soy <30% to 40%
Any solid food <16%
Soy CM <30% to 40%
Any solid food <16%
Solid food (any) Another solid food <44%
CM or soy <25%
Legumes* Soy <80%
Grains: rice, oats, etc* Other grains (including rice) About 50%
Poultry* Other poultry <40%
*Note: where a child already tolerates a food type in a particular group (eg, beans),
clinical reactions to other members of the same group (eg, other legumes) are unlikely.
Caution is warranted in interpreting these data because they were derived from single
centers and from patient populations skewed toward the more severe phenotype of
FPIES and might overestimate the actual risk of coallergy.
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after breast-feeding or the infant has FTT; the mother should seek
immediate consultation with an allergy specialist.15,69 Nutritional
consultation should be considered to assist the elimination diet. If
resolution of symptoms is not accomplished with a maternal die-
tary elimination diet, discontinuation of breast-feeding and intro-
duction of a hypoallergenic formula should be considered.68
Summary Statement 22: Reintroduce the foods triggering
FPIES under a physician’s supervision. [Strength of recom-
mendation: Strong; Evidence strength: Ia/IIb; Evidence
grade: B]
Foods that triggered FPIES reactions in the past should
generally be reintroduced under a physician’s supervision during
a formal OFC or supervised feeding. The timing of such
reintroduction is variable. Placement of secure peripheral intra-
venous access before the OFCmight bewarranted in patients with
past severe reactions requiring an emergency department visit or
hospitalization, as well as in infants and patients with anticipated
difficult intravenous access. Between 45% and 95% of the
challenge reactions were treated with intravenous fluids, steroids,
or both.8,18 In patients with milder reactions, oral rehydration
might be sufficient (Table VII).12 Although some providers might
elect to allow families to try certain foods at home, this should be
a shared decision between medical care providers and caregivers,
accounting for access and distance to local emergency depart-
ments, caregiver comfort, the nature of the trigger food, and the
severity of past FPIES reactions.
Summary Statement 23: Recognize that infants with CM-
or soy-induced FPIES might be at increased risk of having
FPIES to other foods. [Strength of recommendation: Strong;
Evidence strength: III; Evidence grade: C]
The majority of children (65% to 80%) have FPIES to a single
food, most commonly CM.4,5,9 In a large US case series at a ter-
tiary care center, about 5% to 10% of children reacted to more
than 3 foods, some to as many as 6 or more foods.4,5 Children
with either CM- or soy-induced FPIES can also react to both
foods, with this likelihood being higher among those who had
symptoms of FPIES in the first month of life, although the risk
(Table VIII) or odds of this occurring are not known.4,6,57 In these
infants with early onset of FPIES, it might be prudent to breast-
feed or introduce a hypoallergenic formula in the first 6 to
12 months of life, although data pertaining to primary/secondary
FPIES prevention do not exist. In such potentially dually reactive
children, it is recommended to perform supervised OFCs to intro-
duce the uncertain FPIES trigger.
Children with CM- or soy-induced FPIES can also have an
increased likelihood of reacting to a solid food, most commonly
rice or oat. Current early feeding guidelines do not recommend
delay in introducing complementary foods past 6 months of life
because of FPIES.70-72 A practical ordering for introducing solids
at about 6 months of age at home could start with fruits and veg-
etables, followed by other complementary foods, such as red
meats and cereals (Table IX). If an infant tolerates a variety of
early food proteins, subsequent introduction might be more lib-
eral. Tolerance to one food from the food group is considered a
favorable prognostic indicator for tolerance to other foods from
the same group.32
In an infant with severe CM- and/or soy-induced FPIES,
supervised (eg, in-office) introduction of solids can be considered
to promote implementation of normal dietary variety and prevent
unnecessary avoidance. Supervised OFCs to a mixture of severalsolids can be considered as a way of excluding the risk of severe
reactions to small amounts, followed by gradual build up to
regular age-appropriate serving size at home (S. Miceli Sopo,
personal communication).SECTION VII: NUTRITIONAL MANAGEMENT FOR
FPIES
Summary Statement 24: Provide guidance during the intro-
duction of complementary foods to ensure nutritional ade-
quacy during this time and beyond. [Strength of
Recommendation: Strong; Evidence Strength: III; Grade C]
Children with food allergy have been noted to have deficiencies
in energy, protein, vitamin A, vitamin D, calcium, iron, and
zinc.73-76 Infantile FPIES is a risk for deficiencies caused by dietary
restrictions and delayed introduction of new foods. Limited food
experiences can adversely affect food intake for many years to
come.77 It is commonly recommended that caregivers introduce
a new food as a single ingredient and, in the case of high-risk foods,
to wait at least 4 days before introducing another food to observe
for the development of a reaction.78 Providers should recognize
that even single-food elimination can be associatedwith significant
nutritional deficiency.79 Consultation with a dietitian is highly rec-
ommended to facilitate weaning. Table E3 in this article’s Online
Repository at www.jacionline.org details the nutrients typically
provided by the foods most commonly triggering FPIES.
Summary Statement 25: Do not routinely recommend
avoidance of products with precautionary allergen labeling
in patients with FPIES. [Strength of recommendation:
Weak; Evidence strength: IV; Evidence grade: D]
No studies have identified a reliable threshold dose (TD) in
patients with FPIES. Among 28 children undergoing OFC to CM,
53.6% tolerated 121 mL of CM and 82% tolerated 50 mL of CM
before having a reaction.12 High TDs have been reported.18 How-
ever, further studies have reported a TD of only 0.15 g of protein/
kg body weight in 15 (93.7%) of 16 cases of confirmed FPIES
caused by CM, soy, egg, rice, and oat.36 Therefore strict avoid-
ance of trigger foods is recommended.
Summary Statement 26: Use hypoallergenic formula in
formula-fed infants or infants who can no longer breast-feed
and are given a diagnosis of FPIES caused by CM. [Strength
of recommendation: Strong; Evidence strength: IIa/IIb; Evi-
dence grade: B]
TABLE IX. Empiric guidelines for selecting weaning foods in infants with FPIES
Ages and stages Lower-risk foods* Moderate-risk foods* Higher-risk foods*
4-6 mo (as per AAP, CoN) Vegetables
If developmentally appropriate and safe and
nutritious foods are available:
d Begin with smooth, thin purees and progress to
thicker purees
d Choose foods that are high in iron
d Add vegetables and fruits
Broccoli, cauliflower, parsnip,
turnip, pumpkin
Squash, carrot, white potato,
green bean (legume)
Sweet potato, green
pea (legume)
6 mo (as per WHO) Fruits
Complementary feeding should begin no later than 6
mo of age:
d In the breast-fed infant, high-iron foods or
supplemental iron (1 mg/kg/d) are suggested
by 6 mo of age
d Continue to expand variety of fruits, vegeta-
bles, legumes, grains, meats, and other foods
as tolerated.
Blueberries, strawberries, plum,
watermelon, peach, avocado
Apple, pear, orange Banana
8 mo of age or when developmentally appropriate: High-iron foods
d Offer soft-cooked and bite-and-dissolve
textures from around 8 mo of age or as
tolerated by infant.
Lamb, fortified quinoa cereal, millet Beef, fortified grits and
corn cereal, wheat
(whole wheat and fortified),
fortified barley cereal
Higher-iron foods: fortified,
infant rice and oat cereals
12 mo of age or when developmentally appropriate: Other
d Offer modified tolerated foods from the family:
table-chopped meats, soft cooked vegetables,
grains, and fruits
Tree nuts and seed butters*
(sesame, sunflower, etc.)
*Thinned with water or infant
puree for appropriate infant
texture and to prevent choking
Peanut, other legumes
(other than green pea)
Milk, soy, poultry, egg, fish
This table should be considered in the context of the following notes:
A. Exclusive breast-feeding until 4 to 6 months of age and continuing breast-feeding through the first year of life or longer as long as mutually desired by both mother and child
(Baker RD, Greer FR, Committee on Nutrition American Academy of Pediatrics. Diagnosis and prevention of iron deficiency and iron-deficiency anemia in infants and young
children (0-3 years of age). Pediatrics 2010;126:1040-50).
B. If an infant tolerates a variety of early foods, subsequent introduction can be more liberal. Additionally, tolerance to one food in a food group (green pea) is considered a
favorable prognostic indicator for tolerance of other foods from the same group (legumes; Sicherer SH. Food protein-induced enterocolitis syndrome: case presentations and
management lessons. J Allergy Clin Immunol 2005;115:149-56).
AAP, CoN, American Academy of Pediatrics, Committee on Nutrition; WHO, World Health Organization.
*Risk assessment is based on the clinical experience and published reports of FPIES triggers.
J ALLERGY CLIN IMMUNOL
VOLUME 139, NUMBER 4
NOWAK-WE˛GRZYN ET AL 1123The official guidelines1 recommend a hypoallergenic formula
for the treatment of FPIES based on several studies demonstrating
that most children tolerated extensively hydrolyzed formula,
although there are selected children who exclusively tolerate
AAFs.7,8,80-82 AAFs are the only completely nonallergenic for-
mulas and can be effective in patients not responding to exten-
sively hydrolyzed formulas and those with FTT. Soy formula
might be an acceptable alternative, especially in infants older
than 6 months; however, cautious introduction is warranted
because of the potential for coreactivity between patients with
soy-induced FPIES and those with CM-induced FPIES.
Summary Statement 27: Monitor growth (weight and
height/length) regularly in children with FPIES. [Strength
of recommendation: Moderate; Evidence strength: III; Evi-
dence grade: C]
Nowak and others22,32,42,83,84 reported that infants with CM- or
soy-induced FPIES exposed to these proteins on a daily basis typi-
cally manifest poor weight gain, weight loss, or FTT that resolves
with elimination of the implicated food. Poor growth in children
with FPIESwho have successfully eliminated the implicated food
and remain asymptomatic has not been reported. Children with
FPIES and multiple food avoidances or difficulty advancing the
diet might be at increased risk. Growth (weight, length/height,
and head circumference) should be assessed at regular intervals
based on national standards.1,85,86Summary Statement 28: Recommend foods that enhance
developmental skills in infants in the complementary
feeding period to prevent aversive feeding behaviors and
delay in the development of food acceptance and feeding
skills. [Strength of recommendation: Weak; Evidence
strength: IV; Evidence grade: D]
Timely introduction of various tastes and textures affects flavor
acceptance, feeding skills, and eating behaviors.87-93 Finding
appropriate flavors and textures for infants and children with
FPIES requires creativity when multiple solid foods are
restricted.93 Many textures can be provided, even if only 1 food
is tolerated, because a single fruit or vegetable can be prepared
into a thin or thick puree, pureed with lumps, soft cooked for
finger foods, or freeze-dried or fried/oven baked in refined oil
for a crispy crunchy texture (Table IX).SECTION VIII: NATURAL HISTORY OF FPIES
Summary Statement 29: Recognize that the age of develop-
ment of tolerance in patients with FPIES varies by type of
food trigger and country of origin. [Strength of recommenda-
tion: Strong; Evidence strength: IIa/IIb; Evidence grade: B]
Development of tolerance in patients with CM-induced FPIES,
soy-induced FPIES, or both has been reported to occur at an
earlier age than tolerance in patients with grain- or other food-
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selection bias influence these estimates. The average reported
age of tolerance to grains is 35 months, and that to other solid
foods is 42months. The average reported age of tolerance to soy is
approximately 12 months but ranges from 6 months to greater
than 22 years of age.4,5,17 In a large population-based cohort study
from Israel, for patients with CM-induced FPIES, 60% had toler-
ance by 1 year, 75% by 2 years, and 85% by 3 years.12 In a large
US case series the median age of tolerance was 6.7 years. Howev-
er, data from a challenge-based study in Korea noted that signif-
icant rates of tolerance to CM- and soy-induced FPIES might
occur more rapidly (12 and 6 months, respectively) than previ-
ously assumed.11 In pooling the available data from multiple
small cohorts, the age of CM tolerance appears to be around
3 years, but recent large cohorts found a later age of toler-
ance.5,9-12,18,36,37,49,54,57,81,94-102 However, these data were not
derived from a targeted study to determine a firm age of resolution
and thus might be biased toward older ages. In a large US case se-
ries the median age of resolution for CM-induced FPIES was
5.1 years, and in the United Kingdom 25% of the patients had
CM-induced FPIES persist at 8 years of age.5,103 Data from the
same large US case series noted that median ages of resolution
were 4.7 years for rice and 4.0 years for oat. Several studies
observed that patients with CM-induced FPIES and positive
CM-induced SPT responses have a more protracted course and
older age of tolerance (approximately 13.8 years) compared
with those with negative SPT responses.4
Summary Statement 30: Evaluate patients with FPIES at
regular intervals according to the patient’s age and food
allergen to determine whether she or he is still allergic.
[Strength of recommendation: Strong; Evidence strength:
IIb/III; Evidence grade: C]
The ideal timing of OFCs to determine resolution has not been
systematically studied but can vary considerably by country,
nutritional and social food importance, and individual preference.
In the United States diagnostic OFCs are usually attempted within
12 to 18 months after the most recent reaction.3,32 Korean data
suggest children might be ready within a year of diagnosis, with
tolerance rates to CM and soy ranging between 27% and 75%
at 6 months, 42% and 91% and 8 months, and 64% and 92% at
10 months, respectively.11 CM-induced FPIES resolved in all
children by age 2 years, and soy-induced FPIES resolved by
age 14 months; 50% of CM-induced FPIES resolved within first
year of life, 89% by age 2 years, and 90% by age 3 years.12 In
contrast, retrospective series from the United States report lower
rates of resolution of FPIES to CM or soy: 35% by age 2 years,
70% by age 3 years, and 85% by age 5 years.4,5 These differences
likely reflect various study designs, provider preferences, interna-
tional differences in the approach to such patients, or selection
bias towardmore severe and persistent phenotype among children
evaluated at the referral allergy centers compared with those iden-
tified from the general population.4,11,104 There are no data on res-
olution of FPIES to seafood in older children and adults. Periodic
re-evaluations should be similarly considered in adult patients.ASSESSMENT OF FUTURE NEEDS
The following areas have been identified as priorities for
advancing the care of patients with FPIES:
1. characterize chronic FPIES;
2. establish FPIES prevalence;3. identify FPIES risk factors;
4. validate the proposed diagnostic criteria;
5. standardize the OFC protocol and criteria for challenge
positivity;
6. determine the pathophysiology of acute and chronic
FPIES;
7. understand the relationship between atopy and FPIES;
8. develop noninvasive biomarkers for diagnosis and for
monitoring for resolution;
9. develop therapeutic approaches to accelerate FPIES
resolution;
10. determine the role of ondansetron in managing FPIES
reactions;
11. determine whether extensively heated (baked) CM and
egg white proteins can be tolerated by children with
FPIES to these foods;
12. perform systematic evaluation of the prevalence of
nutrient deficiencies, poor growth, and feeding difficulties
in patients with FPIES and provide guidance for preven-
tative intervention; and
13. perform longitudinal cohort studies to better determine
outcomes and the natural history of FPIES in children
and adults.CONCLUSION
The consensus document provides the first international
evidence-based guidelines to improve the diagnosis and man-
agement of patients with FPIES. It also identifies unmet needs
and future directions for research. Research on prevalence,
pathophysiology, diagnostic markers, and future treatments is
necessary to improve the care of patients with FPIES. These
guidelines will be updated periodically as more evidence
becomes available.
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FIG E1. Scheme of a comprehensive literature search run in PubMed/Medline, Web of Science, and
Embase.
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TABLE E1. Age of onset or diagnosis of FPIES (CM/soy vs solid-food triggers)*
Reference Country
Only CM/soy
FPIES
investigated
Overall age of
onset/
diagnosis (mo)
Age onset/
diagnosis of CM/
soy FPIES (mo)
Age onset/
diagnosis of
solid-food
FPIES (mo)
Atypical FPIES*
SPT ssIgE
Nomura et al13 Japan Yes (CM) — 0.28 (0.1-0.82) — — 8/14 (57%)
0.59 (0.34-1.20) 6/16 (38%)
Powell14 United States Yes (CM) — 0.46 (0.14-2.39) — — —
Gryboski42 United States Yes (CM) — 0.25 (0.07-4) — — —
Katz et al12 Israel Yes (CM) — 1 (0-6.4) — 2/44 (5%) —
Nowak-Wegrzyn
et al22
United States No — 1 (0.08-12) 5.5 (3-7) 0/44 (0%) 3/44 (7%)
McDonald et al26 United States Yes (CM/soy) — 1 (0.04-3) — — —
Hwang et al11 South Korea Yes (CM/soy) — 1.28 (0.46-2.1) — — —
Chung et al24 South Korea Yes (CM) 1.75 (—) 1.75 (—) — 0/28 (0%) 0/28 (0%)
Sicherer et al8 United States No 2 (0.25-108) 2.0 (0.25-108) 6 (5-24) 1/20 (5%) 5/20 (25%)
Fogg et al36 United States No 2 (0.25-9) 2 (0.25-4) 4.5 (4-9) — —
Sopo et al18 Italy No 5.1 (5.10) 3.5 (2.40)§ 10.6 (6.70) 0/66 (0%) —
Mehr et al9 Australia No 5.6 (2.70) 4.9 (2.60) 6.1 (1.70) 1/35 (3%) —
Caubet et al4k United States No 4 (2-6) 5 (2-10) 7 (6-12) 39/160 (24%) had positive
SPT and/or ssIgE results
Ruffner et al5 United States No 9.7 (10.20) 7 (0.70) 12.1 (1.10) 26/721 (4%) —
ssIgE, Serum sIgE antibody.
*Data are from studies in which age of onset/diagnosis was recorded. Data are represented as either mean age of onset/diagnosis (SD) or median age of onset/diagnosis (range),
unless otherwise specified.
Figure relates to cluster 1 analysis performed (both clusters representative of FPIES cases).
Figure relates to cluster 2 analysis performed (both clusters representative of FPIES cases).
§Figure relates to CM-induced FPIES only (3 soy cases included with other foods).
kData are represented as medians (interquartile ranges).
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TABLE E2. Case series examining cases of FPIES*
Reference Year Study design Definition used Country
No. of
patients
Study
duration (y) Data on all triggers Center
Male
sex (%)
Eczema
(%)
IgE FA
(%)
Caubet et al4 2014 Prospective 1
retrospective
Their own (modified
Powell)
United States 160 10 Yes; CM, soy, rice, oat, seafood One allergy clinic 54 57 11
Ruffner et al5 2013 Retrospective Their own United States 462 5 Yes; CM, soy, rice, oat, egg One hospital 60 34 —
Fogg et al36 2006 Prospective Sicherer et al United States 19 1.5 Yes; CM, soy, rice, oat, egg Single allergy clinic 53 11 —
Nowak-Wegrzyn et al22 2003 Retrospective Sicherer et al United States 44 5 Yes; CM, soy, rice, oat, barley Two allergy clinics 59 34 —
Sicherer et al8 1998 Retrospective Their own United States 20 6 Yes; CM, soy, rice, green pea, poultry Single allergy clinic 44 31 15
Burks et al7 1994 Prospective Their own United States 22 1.5 CM/soy One hospital — — —
McDonald et al26 1984 Prospective Powell United States 10 — CM/soy One hospital — — —
Powell14§ 1976 Retrospective Their own United States 9 — CM/soy Their own — — —
Gryboski42§ 1967 Retrospective None set United States 21 16 CM One hospital 90 14 —
Katz et al12 2011 Prospective Sicherer et al Israel 44 2 CM One hospital 52 7
Levy and Danon20 2003 Retrospective Their own Israel 6 6 Solid food triggers; chicken, turkey,
green pea, lentil
One hospital 67 — —
Hsu and Mehr, PC 2012 Retrospective Sicherer et al Australia 38 4 Yes, but only egg presented One hospital 53 — —
Mehr et al9 2009 Retrospective Sicherer et al Australia 35 16 Yes; rice, soy, CM, vegetables Single allergy clinic 57 51 11
Nomura et al17 2011 Retrospective Powell Japan 30 3 CM Japanese database 50 — —
Hwang et al11 2009 Prospective Powell Korea 23 4 CM/soy One hospital 70 0 —
Chung et al24 2002 Prospective Sicherer et al Korea 28 — CM One hospital — — —
Sopo et al18 2012 Retrospective Their own/Powell Italy 66 7 Yes; CM, fish, egg, rice Three allergy clinics 61 9 2
—, Not available; FA, IgE-mediated food allergy (ie, a positive serum sIgE antibody and IgE-mediated clinical reaction to a separate food protein not causing FPIES); PC, personal communication with corresponding author.
*Case series were only included where a definition of FPIES was provided and consecutive cases presenting to a health care setting were examined.
Data were only available for infants with typical FPIES (n 5 16).
Most common food allergens listed.
§In these series chronic FPIES or a combination of cases of acute/chronic FPIES was reported.
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TABLE E3. Nutritionally important FPIES-implicated foods and the main nutrients they provide with alternative dietary sources
Provoking foods Main nutrients Alternative sources
CM Macronutrients: protein, fat Hypoallergenic formula, breast milk*
Minerals and trace elements: calcium, magnesium, phosphorus,
iodine
Older toddlers (>2 y): fortified alternative beverages such as
soy, rice, hemp, almond, oat, coconut, if tolerated
Vitamins: A, B6, B12, D, riboflavin, pantothenic acid
Rice, oat, barley, and
wheat grains
Carbohydrate, magnesium, phosphorus, potassium, zinc Flours and especially enriched cereal and cereal products
made from quinoa, buckwheat, millet, corn, legumes: B
vitamins, iron, zinc, carbohydrates
Frequently in enriched cereal products: iron, thiamine, niacin,
riboflavin, folate, choline, calcium, zinc, selenium
Dark green vegetables: B vitamins, vitamin A, B6, folate,
vitamin C
Starchy vegetables: carbohydrates
Sesame seeds (as tahini): protein, calcium, iron, copper,
manganese, zinc, thiamine, riboflavin, niacin, pantothenic
acid, vitamin B6, folate, omega 3 and 6 fatty acids
Beef and lamb: iron, zinc, choline
Soy Calcium, phosphorus, magnesium, iron, zinc, thiamine,
riboflavin, vitamin B6, folate
Hypoallergenic formula
Other legumes
Eggs Protein, iron, selenium, biotin, vitamin B12, pantothenic acid,
folate, riboflavin, choline
Meats: protein, iron, B12, choline
Fish/shellfish Protein, iodine Seeds, such as flax and sesame: omega 3 fatty acids, protein, fat
Fatty fish: Vitamins A and D, choline, omega-3 fatty acids Iodized salt- small amounts- iodine
Chicken/turkey/lamb Protein, selenium, phosphorus, vitamin B12, potassium,
choline, zinc, iron
Beef and pork: protein, fat, iron, B12, zinc, choline,
phosphorous
Note: When choosing plant-based sources of iron (nonheme iron sources), it is beneficial to include dietary sources of vitamin C to improve iron absorption. Boldface nutrients are
the main nutrients of concern with eliminated foods/food groups. Italicized and boldface foods are the best nutritional substitutes for the main nutrients of concern.
*Breast milk alone does not provide adequate vitamin D, iron, zinc, or protein for older infants (>6 months); consider also solid-food choices to meet these nutrient needs.
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